Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis

医学 特应性皮炎 湿疹面积及严重程度指数 内科学 相对风险 安慰剂 置信区间 随机对照试验 胃肠病学 不利影响 免疫学 病理 替代医学
作者
Chenyang Li,Xun Sun,Kun Zhao,Fanxiang Meng,Dan Li,Zhenzhen Mu,Xiuping Han
出处
期刊:Dermatology [Karger Publishers]
卷期号:238 (4): 725-735 被引量:25
标识
DOI:10.1159/000518541
摘要

<b><i>Background:</i></b> Current therapeutic options for atopic dermatitis (AD) are limited. Janus kinase (JAK) inhibitors may be viable alternatives. <b><i>Objectives:</i></b> To assess the efficacy and safety of JAK inhibitors for AD treatment. <b><i>Methods:</i></b> We searched PubMed, Embase, the Cochrane Controlled Register of Trials, Web of Science, Global Resource of Eczema Trials database, and ClinicalTrials.gov from inception to September 1, 2020. Randomized clinical trials (RCTs) comparing JAK inhibitors with placebo/vehicle treatment for AD patients were included. The primary study outcomes included (1) the change (%) from the Eczema Area and Severity Index (EASI) baseline expressed as weighted mean difference (WMD) and 95% confidence interval (95% CI), and (2) the Investigator’s Global Assessment (IGA) response and safety outcomes expressed as relative risk (RR) and 95% CI. <b><i>Results:</i></b> We included 14 RCTs published in 13 studies (3,822 patients). Treatment with JAK inhibitors significantly improved IGA response (RR 2.83, 95% CI 2.25–3.56, <i>p</i> &#x3c; 0.001) and EASI score (WMD –28.82, 95% CI –34.48 to −23.16, <i>p</i> &#x3c; 0.001). JAK inhibitor treatment achieved the largest improvement in both IGA response (RR 3.59, 95% CI 2.66–4.84, <i>p</i> &#x3c; 0.001) and EASI score (WMD –42.00, 95% CI –48.64 to −35.36, <i>p</i> &#x3c; 0.001) by week 4 of treatment. Topical JAK inhibitors were significantly more efficacious than oral inhibitors. Upadacitinib treatment for 4 weeks was most effective in reducing EASI score (WMD –53.92, 95% CI –69.26 to −38.58, <i>p</i> &#x3c; 0.001), while abrocitinib for 4 weeks led to the most effective IGA response (RR 5.47, 95% CI 2.74–10.93, <i>p</i> &#x3c; 0.001). There was no difference in the frequency of adverse events (AEs) leading to discontinuation; however, JAK inhibitors use, especially abrocitinib, led to a higher incidence of treatment-emergent AEs (RR 1.25, 95% CI 1.10–1.42, <i>p</i> = 0.001). <b><i>Conclusion:</i></b> Our results imply that JAK inhibitors are an effective and safe AD treatment. Nevertheless, further trials with longer duration and head-to-head comparisons of different JAK inhibitors are needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
光亮的自行车完成签到,获得积分0
3秒前
4秒前
wangwei发布了新的文献求助10
7秒前
凶狠的白桃完成签到 ,获得积分10
7秒前
innocence2000完成签到 ,获得积分10
9秒前
牛马发布了新的文献求助10
13秒前
小胖完成签到 ,获得积分10
17秒前
柚子皮完成签到,获得积分10
18秒前
21秒前
hakuna_matata完成签到 ,获得积分10
21秒前
柚子皮发布了新的文献求助10
24秒前
Q_完成签到 ,获得积分10
25秒前
舒心靖琪完成签到 ,获得积分10
31秒前
MUAN完成签到 ,获得积分10
32秒前
swordshine完成签到,获得积分10
32秒前
任性的皮卡丘完成签到 ,获得积分10
35秒前
linhuafeng完成签到 ,获得积分10
35秒前
简奥斯汀完成签到 ,获得积分10
39秒前
克姑美完成签到 ,获得积分10
40秒前
小杨完成签到 ,获得积分10
41秒前
44秒前
闪闪的谷梦完成签到 ,获得积分10
47秒前
无奈的萝完成签到,获得积分10
51秒前
aldehyde应助leo采纳,获得10
52秒前
研友_nqv5WZ完成签到 ,获得积分10
55秒前
老实乌冬面完成签到 ,获得积分10
55秒前
58秒前
59秒前
shxxy123完成签到 ,获得积分10
59秒前
研都不研了完成签到 ,获得积分10
1分钟前
1分钟前
含糊的代丝完成签到 ,获得积分10
1分钟前
1分钟前
一只滦完成签到,获得积分10
1分钟前
xiaoyi完成签到 ,获得积分10
1分钟前
专一的傲白完成签到 ,获得积分10
1分钟前
1分钟前
tuanhust完成签到,获得积分0
1分钟前
跳跃的白云完成签到 ,获得积分10
1分钟前
穆奕完成签到 ,获得积分10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968559
求助须知:如何正确求助?哪些是违规求助? 3513358
关于积分的说明 11167370
捐赠科研通 3248804
什么是DOI,文献DOI怎么找? 1794465
邀请新用户注册赠送积分活动 875116
科研通“疑难数据库(出版商)”最低求助积分说明 804664